NEWS
VitaPCR™ Influenza A&B/SARS-CoV-2 assay Receives CE Mark
Credo Diagnostics Biomedical VitaPCR™ SARS-CoV-2 Assay Garners CE Mark.
Credo Diagnostics Biomedical is finalizing a rapid point-of-care molecular test for the detection of novel Coronavirus COVID-19 in 20 minutes.
Credo Diagnostics Biomedical will be located at the booth Z4.D29, where it will be showcasing its product line of rapid molecular diagnostic and laboratory workflow solutions to potential business partners.
VitaPCR™, the Point-of-Care Molecular Diagnostic Test to Detect Influenza A/B under 20 Minutes at the same Price Level as RIDTs, to be Launched at the AACC Clinical Expo (Booth #4339).
Credo Diagnostics Biomedical will be featured in the newest episode of Advancements with Ted Danson that will broadcast Nationwide via CNBC on Saturday, September 21st @11:00am ET.